Brown University Purchases 141,500 Shares of COMPASS Pathways plc (NASDAQ:CMPS)

Brown University grew its holdings in COMPASS Pathways plc (NASDAQ:CMPS - Free Report) by 194.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 214,200 shares of the company's stock after acquiring an additional 141,500 shares during the quarter. COMPASS Pathways accounts for about 0.3% of Brown University's investment portfolio, making the stock its 12th largest holding. Brown University owned about 0.31% of COMPASS Pathways worth $810,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of CMPS. Essential Planning LLC. acquired a new position in COMPASS Pathways during the fourth quarter valued at approximately $70,000. Wealthfront Advisers LLC bought a new position in COMPASS Pathways during the 4th quarter worth $43,000. Conservest Capital Advisors Inc. increased its stake in COMPASS Pathways by 28.9% during the 4th quarter. Conservest Capital Advisors Inc. now owns 13,363 shares of the company's stock worth $51,000 after acquiring an additional 3,000 shares during the period. SVB Wealth LLC acquired a new stake in shares of COMPASS Pathways in the 4th quarter valued at $101,000. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in shares of COMPASS Pathways in the 4th quarter valued at $41,000. 46.19% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Canaccord Genuity Group cut their price objective on COMPASS Pathways from $23.00 to $15.00 and set a "buy" rating on the stock in a report on Friday, February 28th. Royal Bank of Canada reissued an "outperform" rating and issued a $18.00 price objective on shares of COMPASS Pathways in a research report on Wednesday, January 15th. Stifel Nicolaus began coverage on COMPASS Pathways in a research report on Thursday, February 27th. They issued a "buy" rating and a $11.00 price objective for the company. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $45.00 target price on shares of COMPASS Pathways in a research report on Tuesday, March 4th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, COMPASS Pathways presently has a consensus rating of "Buy" and a consensus price target of $21.83.

Remove Ads

COMPASS Pathways Stock Down 3.3 %

CMPS traded down $0.10 during mid-day trading on Thursday, reaching $2.96. 1,453,483 shares of the stock were exchanged, compared to its average volume of 744,558. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.91 and a current ratio of 8.91. The stock has a market capitalization of $274.31 million, a PE ratio of -1.35 and a beta of 2.29. The company has a 50 day moving average price of $3.93 and a two-hundred day moving average price of $4.91. COMPASS Pathways plc has a 1 year low of $2.94 and a 1 year high of $10.31.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported ($0.63) EPS for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.01). As a group, research analysts anticipate that COMPASS Pathways plc will post -2.33 EPS for the current year.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.